Effective communication between doctors and patients when switching from a branded biologic to a biosimilar is needed to overcome the potential adverse consequences of the ‘nocebo’ effect, according to Professor Fabrizio Benedetti of the department of neuroscience within Italy’s University of Turin.
Speaking at a European League Against Rheumatism (EULAR) virtual symposium on real-world evidence on the subject of “effective communication in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?